Cardiovascular Department, Ospedale S.Donato
Arezzo, AR, 52100, Italy
NCT Number: NCT00827788
The purpose of this study is to determine the incidence of contrast induced nephropathy and myocardial tissue reperfusion following iso-osmolar iodixanol or ipo-osmolar iopromide administration in patients with acute myocardial infarction undergoing primary PCI.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Arezzo, AR, 52100, Italy
This is a multicentric randomized comparison between iso-osmolar and ipo-osmolar contrast agents in patients treated with primary PCI with the evaluation of contrast-induced nephropathy incidence and myocardial tissue reperfusion. The study was designed as a non-inferiority trial.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
Other names: Visipaque®
Low-osmolar contrast medium (Iopromide) will be administered during PCI
Other names: Ultravist®
Time frame: days 1, 2, 3, and at discharge
Time frame: before and after primary PCI
Time frame: after primary PCI
Time frame: after PCI
Time frame: after primary PCI
Time frame: 1, 6, 12 months
Time frame: days 1, 2, 3, and at discharge
Time frame: days 1, 2, 3, and at discharge
Ospedale San Donato
Other
The Contrast Media and Nephrotoxicity Following Coronary Revascularization by Primary Angioplasty for Acute Myocardial Infarction. The CONTRAST-AMI Study.
Acronym: CONTRAST-AMI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07561801
Chronic Disease, Chronic Kidney Disease
Tanta, El-Gharbia, Egypt
View Trial DetailsNCT00639912
Contrast Induced Nephropathy
Ferrara, Emilia-Romagna, Italy
View Trial DetailsNCT02516072
Contrast Induced Nephropathy, Remote Ischaemic Preconditioning
Singapore
View Trial DetailsNCT01999517
Contrast Induced Nephropathy
Miami Beach, Florida, United States
View Trial Details